CL2022000110A1 - Inhibidores de parp1 - Google Patents
Inhibidores de parp1Info
- Publication number
- CL2022000110A1 CL2022000110A1 CL2022000110A CL2022000110A CL2022000110A1 CL 2022000110 A1 CL2022000110 A1 CL 2022000110A1 CL 2022000110 A CL2022000110 A CL 2022000110A CL 2022000110 A CL2022000110 A CL 2022000110A CL 2022000110 A1 CL2022000110 A1 CL 2022000110A1
- Authority
- CL
- Chile
- Prior art keywords
- parp1 inhibitors
- parp1
- inhibitors
- medicine
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de azaquinolona de fórmula (I), y a su uso en medicina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962876065P | 2019-07-19 | 2019-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022000110A1 true CL2022000110A1 (es) | 2022-09-20 |
Family
ID=71728735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022000110A CL2022000110A1 (es) | 2019-07-19 | 2022-01-17 | Inhibidores de parp1 |
Country Status (21)
Country | Link |
---|---|
US (2) | US11325906B2 (es) |
EP (1) | EP3999506A1 (es) |
JP (1) | JP2022541483A (es) |
KR (1) | KR20220035941A (es) |
CN (1) | CN114144413A (es) |
AR (1) | AR119424A1 (es) |
AU (1) | AU2020318599B2 (es) |
BR (1) | BR112022000534A2 (es) |
CA (1) | CA3145644A1 (es) |
CL (1) | CL2022000110A1 (es) |
CO (1) | CO2022001590A2 (es) |
CR (1) | CR20220070A (es) |
DO (1) | DOP2022000006A (es) |
EC (1) | ECSP22012826A (es) |
IL (1) | IL289534A (es) |
JO (1) | JOP20220008A1 (es) |
MX (1) | MX2022000711A (es) |
PE (1) | PE20221339A1 (es) |
TW (1) | TWI837403B (es) |
UY (1) | UY38793A (es) |
WO (1) | WO2021013735A1 (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022532342A (ja) | 2019-05-14 | 2022-07-14 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
TW202228693A (zh) * | 2020-10-08 | 2022-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
IL301921A (en) | 2020-10-09 | 2023-06-01 | Daiichi Sankyo Co Ltd | Combining an antibody-drug conjugate and a selective 1PARP inhibitor |
MX2023011241A (es) | 2021-03-23 | 2023-10-03 | Nuvation Bio Inc | Compuestos dirigidos a receptores de hormonas nucleares contra el cancer. |
JP2024514223A (ja) * | 2021-04-19 | 2024-03-28 | シンセラ, インコーポレイテッド | Parp1阻害薬及びその使用 |
CN117279916A (zh) * | 2021-04-22 | 2023-12-22 | 微境生物医药科技(上海)有限公司 | 含哌嗪结构的parp抑制剂、其制备方法及医药用途 |
TW202309026A (zh) * | 2021-04-23 | 2023-03-01 | 大陸商上海翰森生物醫藥科技有限公司 | 雜環類衍生物抑制劑、其製備方法和應用 |
WO2022222966A1 (zh) * | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 一种选择性parp1抑制剂及其应用 |
CN115232121B (zh) * | 2021-04-23 | 2023-08-29 | 成都百裕制药股份有限公司 | 吡啶衍生物及其在医药上的应用 |
TW202304911A (zh) * | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | 吡啶醯胺類化合物 |
EP4334314A1 (en) * | 2021-05-03 | 2024-03-13 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CA3219248A1 (en) * | 2021-05-18 | 2022-11-24 | Hyun Ju Cha | Parp inhibitor-resistant cancer therapeutic agent |
KR20240012437A (ko) | 2021-05-24 | 2024-01-29 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 질소 함유 헤테로사이클릭 화합물, 이의 제조 방법 및 의학에서 이의 응용 |
IL309388A (en) * | 2021-06-16 | 2024-02-01 | Repare Therapeutics Inc | Combining ATR inhibitors and PARP inhibitors for cancer treatment |
WO2022271547A1 (en) | 2021-06-21 | 2022-12-29 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
WO2023036285A1 (zh) * | 2021-09-09 | 2023-03-16 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药(杭州)有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
WO2023046158A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
WO2023046149A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
WO2023051812A1 (zh) | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 含氮杂环衍生物parp抑制剂及其用途 |
CN118019740A (zh) * | 2021-09-30 | 2024-05-10 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
CN118043323A (zh) | 2021-09-30 | 2024-05-14 | 西藏海思科制药有限公司 | 双环衍生物parp抑制剂及其用途 |
IL311376A (en) * | 2021-10-01 | 2024-05-01 | Xinthera Inc | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES |
WO2023061406A1 (zh) * | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
CA3235698A1 (en) | 2021-10-22 | 2023-04-27 | Yao Li | Parp-1 degradation agent and use thereof |
CA3238116A1 (en) | 2021-11-18 | 2023-05-25 | Matthew Simon SUNG | Combination of antibody-drug conjugate and parp1 selective inhibitor |
AU2022390101A1 (en) | 2021-11-19 | 2024-06-06 | Kangbaida (Sichuan) Biotechnology Co., Ltd. | Selective parp1 inhibitor and application thereof |
WO2023096915A1 (en) * | 2021-11-24 | 2023-06-01 | Slap Pharmaceuticals Llc | Multicyclic compounds |
CA3241338A1 (en) * | 2021-12-17 | 2023-06-22 | Yongqi Deng | Parp inhibitor, pharmaceutical composition comprising same, and use thereof |
CA3242082A1 (en) * | 2021-12-21 | 2023-06-29 | Astrazeneca Ab | Methods of treating brain tumours and neuroblastomas |
TW202332438A (zh) * | 2021-12-22 | 2023-08-16 | 美商思諾維新醫藥公司 | Parp1抑制劑 |
WO2023133413A1 (en) * | 2022-01-07 | 2023-07-13 | Slap Pharmaceuticals Llc | Multicyclic compounds |
WO2023134647A1 (zh) * | 2022-01-13 | 2023-07-20 | 优领医药科技(香港)有限公司 | 含哌嗪并环类衍生物、其药学上可接受的盐及其制备方法和应用 |
WO2023138541A1 (zh) * | 2022-01-20 | 2023-07-27 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
WO2023141290A1 (en) | 2022-01-21 | 2023-07-27 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
WO2023146957A1 (en) * | 2022-01-27 | 2023-08-03 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
WO2023146960A1 (en) * | 2022-01-28 | 2023-08-03 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
WO2023165501A1 (zh) * | 2022-03-01 | 2023-09-07 | 杭州领业医药科技有限公司 | Azd5305的晶型及其制备方法和用途 |
WO2023178035A1 (en) * | 2022-03-14 | 2023-09-21 | Slap Pharmaceuticals Llc | Multicyclic compounds |
WO2023194530A1 (en) | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Combination therapy for treating cancer |
WO2023194528A1 (en) | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Combination therapy for treating cancer |
WO2023194525A1 (en) | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Combination therapy for treating cancer |
WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
WO2023207284A1 (en) * | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Piperazine derivatives as parp1 inhibitiors |
TW202400596A (zh) | 2022-04-28 | 2024-01-01 | 美商辛瑟拉股份有限公司 | 三環parp1抑制劑及其用途 |
WO2023207283A1 (en) * | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Compounds as parp1 inhibitiors |
WO2023217045A1 (zh) * | 2022-05-07 | 2023-11-16 | 南京明德新药研发有限公司 | 选择性抑制parp1的氟代喹喔啉酮衍生物 |
WO2023227052A1 (zh) * | 2022-05-25 | 2023-11-30 | 西藏海思科制药有限公司 | 双环衍生物parp抑制剂及其用途 |
WO2023242302A1 (en) | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
CN115919859B (zh) * | 2022-07-14 | 2024-01-05 | 四川海思科制药有限公司 | 一种杂芳基衍生物的药物组合物及其在医药上的应用 |
TW202408509A (zh) * | 2022-07-14 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 雜芳基衍生物的藥物組合物及其在醫藥上的應用 |
CN115232129B (zh) * | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
WO2024041608A1 (zh) * | 2022-08-24 | 2024-02-29 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂的晶体形式及其用途 |
WO2024041605A1 (zh) * | 2022-08-24 | 2024-02-29 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途 |
WO2024041643A1 (zh) * | 2022-08-25 | 2024-02-29 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
WO2024046420A1 (zh) * | 2022-08-31 | 2024-03-07 | 江苏恒瑞医药股份有限公司 | 稠合二环类化合物、其制备方法及其在医药上的应用 |
CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
CN118119629A (zh) * | 2022-09-30 | 2024-05-31 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
TW202415658A (zh) * | 2022-09-30 | 2024-04-16 | 大陸商中國醫藥研究開發中心有限公司 | 含氮雜環類化合物及其醫藥用途 |
US20240174669A1 (en) * | 2022-10-06 | 2024-05-30 | Xinthera, Inc. | Crystalline forms of a parp1 inhibitor |
WO2024083218A1 (zh) * | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 取代四氢吡啶类化合物及其用途 |
CN117917407A (zh) * | 2022-10-20 | 2024-04-23 | 成都赜灵生物医药科技有限公司 | 并杂环类化合物及其用途 |
WO2024083211A1 (zh) * | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 并杂环类氘代化合物及其用途 |
WO2024083204A1 (zh) * | 2022-10-21 | 2024-04-25 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂的盐、晶型及其制备方法和应用 |
WO2024097775A1 (en) * | 2022-11-02 | 2024-05-10 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
WO2024099386A1 (zh) * | 2022-11-10 | 2024-05-16 | 正大天晴药业集团股份有限公司 | 稠合双环化合物 |
WO2024109871A1 (zh) * | 2022-11-23 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 |
WO2024121753A1 (en) | 2022-12-06 | 2024-06-13 | Astrazeneca Ab | Polq inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002503943A (ja) | 1994-08-12 | 2002-02-05 | ミリアド・ジェネティックス・インコーポレイテッド | 17q−連鎖乳癌および卵巣癌感受性遺伝子におけるイン・ビボ突然変異および多形性 |
WO1996005307A2 (en) | 1994-08-12 | 1996-02-22 | Myriad Genetics, Inc. | 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE |
AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
GB2415430B (en) | 2003-03-12 | 2006-07-12 | Kudos Pharm Ltd | Phthalazinone derivatives |
EP1687277B1 (en) | 2003-11-20 | 2018-04-04 | Janssen Pharmaceutica NV | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
UA89618C2 (ru) | 2003-12-05 | 2010-02-25 | Янссен Фармацевтика Н.В. | 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы |
AU2004299183B2 (en) | 2003-12-10 | 2010-09-23 | Janssen Pharmaceutica N.V. | Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
MX2007002318A (es) | 2004-08-26 | 2007-04-17 | Kudos Pharm Ltd | Derivados de ftalazinona substituidos con 4-heteroarilmetilo. |
DK2134691T3 (da) | 2007-03-08 | 2012-05-07 | Janssen Pharmaceutica Nv | Quinolinonderivativer som parp- og tank-inhibitorer |
ES2448870T3 (es) * | 2007-10-26 | 2014-03-17 | Janssen Pharmaceutica, N.V. | Derivados de quinolina como inhibidores de PARP |
UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
US7928105B2 (en) * | 2009-01-23 | 2011-04-19 | Takeda Pharmaceutical Company Limited | Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones |
US8541417B2 (en) * | 2009-07-30 | 2013-09-24 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) polymerase (PARP) inhibitors |
WO2016200101A2 (ko) * | 2015-06-09 | 2016-12-15 | 제일약품주식회사 | 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
-
2020
- 2020-07-17 MX MX2022000711A patent/MX2022000711A/es unknown
- 2020-07-17 PE PE2022000086A patent/PE20221339A1/es unknown
- 2020-07-17 UY UY0001038793A patent/UY38793A/es unknown
- 2020-07-17 TW TW109124347A patent/TWI837403B/zh active
- 2020-07-17 AR ARP200102008A patent/AR119424A1/es unknown
- 2020-07-17 CR CR20220070A patent/CR20220070A/es unknown
- 2020-07-17 AU AU2020318599A patent/AU2020318599B2/en active Active
- 2020-07-17 US US16/931,792 patent/US11325906B2/en active Active
- 2020-07-17 CA CA3145644A patent/CA3145644A1/en active Pending
- 2020-07-17 KR KR1020227005427A patent/KR20220035941A/ko unknown
- 2020-07-17 CN CN202080051330.7A patent/CN114144413A/zh active Pending
- 2020-07-17 JO JOP/2022/0008A patent/JOP20220008A1/ar unknown
- 2020-07-17 WO PCT/EP2020/070306 patent/WO2021013735A1/en active Application Filing
- 2020-07-17 EP EP20743121.4A patent/EP3999506A1/en active Pending
- 2020-07-17 BR BR112022000534A patent/BR112022000534A2/pt unknown
- 2020-07-17 JP JP2022502556A patent/JP2022541483A/ja active Pending
-
2021
- 2021-12-31 IL IL289534A patent/IL289534A/en unknown
-
2022
- 2022-01-17 CL CL2022000110A patent/CL2022000110A1/es unknown
- 2022-01-17 DO DO2022000006A patent/DOP2022000006A/es unknown
- 2022-02-16 CO CONC2022/0001590A patent/CO2022001590A2/es unknown
- 2022-02-17 EC ECSENADI202212826A patent/ECSP22012826A/es unknown
- 2022-04-07 US US17/715,463 patent/US20220227768A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20221339A1 (es) | 2022-09-13 |
US11325906B2 (en) | 2022-05-10 |
AR119424A1 (es) | 2021-12-15 |
EP3999506A1 (en) | 2022-05-25 |
US20210040084A1 (en) | 2021-02-11 |
TWI837403B (zh) | 2024-04-01 |
CR20220070A (es) | 2022-03-21 |
KR20220035941A (ko) | 2022-03-22 |
AU2020318599A1 (en) | 2022-03-10 |
CN114144413A (zh) | 2022-03-04 |
CA3145644A1 (en) | 2021-01-28 |
WO2021013735A1 (en) | 2021-01-28 |
DOP2022000006A (es) | 2022-03-15 |
TW202116750A (zh) | 2021-05-01 |
ECSP22012826A (es) | 2022-03-31 |
AU2020318599B2 (en) | 2023-09-07 |
JP2022541483A (ja) | 2022-09-26 |
US20220227768A1 (en) | 2022-07-21 |
BR112022000534A2 (pt) | 2022-05-10 |
CO2022001590A2 (es) | 2022-03-18 |
UY38793A (es) | 2021-02-26 |
IL289534A (en) | 2022-03-01 |
JOP20220008A1 (ar) | 2023-01-30 |
MX2022000711A (es) | 2022-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP22012826A (es) | Inhibidores de parp1 | |
CY1124726T1 (el) | Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv | |
CL2019000477A1 (es) | Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino. | |
CO2020007244A2 (es) | Inhibidores de kras g12c | |
CO2022003782A2 (es) | Inhibidores de kras g12d | |
CY1124476T1 (el) | Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου | |
AR121273A2 (es) | Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende | |
ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
EA201990615A1 (ru) | Пирролобензодиазепиновые конъюгаты | |
CL2018001586A1 (es) | Compuestos inhibidores de la quinasa de union a tank | |
GEP20237506B (en) | Pcsk9 antagonist compounds | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
CL2018003527A1 (es) | Conjugados de anticuerpo anti-egfr y fármaco. | |
CY1123263T1 (el) | Πολυκυκλικες ενωσεις ως αναστολεις κινασης τυροσινης bruton | |
EA201992147A1 (ru) | Ингибиторы тирозинкиназы брутона | |
CL2019001993A1 (es) | Inhibidores selectivos de jak1. | |
EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
EA201792057A1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
BR112022012410A2 (pt) | Degradadores smarca e usos dos mesmos | |
PH12020550537A1 (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
BR112021011124A2 (pt) | Anelossomos e métodos de uso | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
EA201890075A1 (ru) | Инъецируемые фармацевтические композиции лефамулина | |
CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. |